|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||205.20 - 212.65|
|52 Week Range||131.60 - 212.65|
|Beta (5Y Monthly)||0.48|
|PE Ratio (TTM)||34.20|
|Forward Dividend & Yield||1.69 (0.80%)|
|Ex-Dividend Date||Apr 26, 2021|
|1y Target Est||N/A|
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy.
NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Merck KGaA (OTC PINK:MKGAF) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 2:00 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Deutsche Bank today announced that the presentations from the November 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.